---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249962"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:23:07.803421+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics appoints Dr. Jeffrey W. Sherman to Board of Directors

## Summary
- Board expanded from 5 to 6 members; Dr. Sherman appointed as Class I director through 2024 annual meeting.
- Dr. Sherman is EVP and Chief Medical Officer of Horizon Therapeutics, with extensive biopharma leadership experience.
- Received option to purchase 16,600 shares of common stock, vesting monthly over 36 months.
- Appointed to Nominating and Corporate Governance Committee.

## SEC filing metadata
- accession: 0001193125-23-249962
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312523249962/0001193125-23-249962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312523249962/d517569d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249962
- JSON: https://secwatch.observer/filing/0001193125-23-249962.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249962.txt

## Key facts
- Executive change
  Jeffrey W. Sherman was appointed as Class I Director at Larimar Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000119312523249962/0001193125-23-249962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.